Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34238
- Registration Number
- NCT06351748
- Locations
- 🇨🇳
Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin, China
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 180
- Registration Number
- NCT06323174
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇸🇦National Guard Hospital - Jeddah, Jeddah, Saudi Arabia
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 270
- Registration Number
- NCT06323161
- Locations
- 🇺🇸
Bioclinical Research Alliance, Miami, Florida, United States
🇺🇸Velocity Clinical Res-Dallas, Dallas, Texas, United States
🇺🇸Palm Research Center Inc., Las Vegas, Nevada, United States
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 999
- Registration Number
- NCT06299098
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Foothills Research Center/ CCT Research, Phoenix, Arizona, United States
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT06289504
- Locations
- 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada
Special Use - Results Surveillance on Long-term Use With Wegovy®
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1000
- Registration Number
- NCT06283667
- Locations
- 🇯🇵
Osaki citizen hospital, Diabetes and metabolic disease, Osaki-shi, Miyagi, Japan
🇯🇵Novo Nordisk Investigational Site, Tokyo, Chiyoda City, Japan
🇯🇵Okazaki City Hospital, Aichi, Japan
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06282458
- Locations
- 🇺🇸
SKY Integrative Medical Center, Ridgeland, Mississippi, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Palm Research Center, Las Vegas, Nevada, United States
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1250
- Registration Number
- NCT06260722
- Locations
- 🇺🇸
Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸Deaconess Clinic - Gateway Health Center, Newburgh, Indiana, United States
🇺🇸IMA Clinical Research Monroe - Armand, Monroe, Louisiana, United States
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 272
- Registration Number
- NCT06256549
- Locations
- 🇨🇳
Gan & Lee Pharmaceuticals Co., Ltd, Beijing, China
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- University Hospital "Sestre Milosrdnice"
- Target Recruit Count
- 60
- Registration Number
- NCT06243536
- Locations
- 🇭🇷
UH Sestre milosrdnice, Zagreb, Croatia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.